Critical Survey: OmniAb (NASDAQ:OABI) vs. VYNE Therapeutics (NASDAQ:VYNE)

OmniAb (NASDAQ:OABI) and VYNE Therapeutics (NASDAQ:VYNE) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, risk and institutional ownership.

Earnings & Valuation

This table compares OmniAb and VYNE Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OmniAb	$18.67 million	20.94	-$64.78 million	($0.46)	-5.87
VYNE Therapeutics	$570,000.00	39.90	-$26.48 million	($0.38)	-1.79

VYNE Therapeutics has lower revenue, but higher earnings than OmniAb. OmniAb is trading at a lower price-to-earnings ratio than VYNE Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

72.1% of OmniAb shares are owned by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are owned by institutional investors. 9.8% of OmniAb shares are owned by insiders. Comparatively, 3.0% of VYNE Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for OmniAb and VYNE Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OmniAb	1	0	2	0	2.33
VYNE Therapeutics	1	3	0	0	1.75

OmniAb presently has a consensus target price of $3.00, indicating a potential upside of 11.11%. Given OmniAb’s stronger consensus rating and higher possible upside, analysts plainly believe OmniAb is more favorable than VYNE Therapeutics.

Volatility & Risk

OmniAb has a beta of 0.07, suggesting that its share price is 93% less volatile than the S&P 500. Comparatively, VYNE Therapeutics has a beta of 2, suggesting that its share price is 100% more volatile than the S&P 500.

Profitability

This table compares OmniAb and VYNE Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OmniAb	-187.59%	-20.31%	-18.10%
VYNE Therapeutics	-4,726.21%	-70.42%	-63.46%

Summary

OmniAb beats VYNE Therapeutics on 8 of the 14 factors compared between the two stocks.

About OmniAb

OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.

About VYNE Therapeutics

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.